(Albany, New York) – 2nd Sep 2026 – The market dynamics for Atherosclerotic Cardiovascular Disease (ASCVD) are witnessing steady growth driven by the rising global burden of cardiovascular diseases, increasing prevalence of dyslipidemia and metabolic disorders, growing awareness of cardiovascular risk prevention, and continuous advancements in lipid-lowering therapies. Additionally, the expanding adoption of PCSK9-targeted therapies, RNA-based therapies, and emerging novel approaches targeting lipid metabolism, inflammation, thrombosis, and other cardiovascular pathways are expected to further propel the Atherosclerotic Cardiovascular Disease market during the forecast period.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Atherosclerotic Cardiovascular Disease Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Atherosclerotic Cardiovascular Disease, including historical and forecasted epidemiology, market trends, treatment scenarios, competitive landscape, and emerging therapies across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Atherosclerotic Cardiovascular Disease Market

• The market size for Atherosclerotic Cardiovascular Disease in the leading markets is expected to grow significantly by 2036.

• The 7MM Atherosclerotic Cardiovascular Disease Treatment Market was approximately USD 24,000 million in 2025 and is projected to increase to nearly USD 40,000 million by 2036, reflecting a 4.8% CAGR during 2026–2036.

• According to DelveInsight’s estimates, the total diagnosed prevalent cases of Atherosclerotic Cardiovascular Disease in the 7MM were approximately 65,415,000 in 2025.

• Among the 7MM, the United States accounted for the highest Atherosclerotic Cardiovascular Disease Treatment Market Size in 2025, followed by Germany.

• In 2025, approximately 55% of ASCVD cases in the United States occurred in males, while females accounted for approximately 45%, representing around 17,300,000 male cases and 13,800,000 female cases.

• Among the age groups assessed by DelveInsight, 65 years and above accounted for the highest number of diagnosed ASCVD cases in EU4 and the UK in 2025, with approximately 15,900,000 cases.

• REPATHA (evolocumab) currently dominates the PCSK9 inhibitor market, while LEQVIO (inclisiran) and emerging oral PCSK9 therapies are projected to capture a larger share by 2036.

• In 2025, Evolocumab generated the largest revenue among current ASCVD therapies, with approximately USD 1,500 million in the United States.

• Leading Atherosclerotic Cardiovascular Disease companies, including Amgen/Arrowhead Pharmaceuticals, NewAmsterdam Pharma and Menarini Group, Resverlogix, Ionis Pharmaceuticals/Novartis, LIB Therapeutics, Sanofi/Regeneron Pharmaceuticals, AstraZeneca, Merck, Novo Nordisk, and others, are actively developing innovative therapies expected to transform the ASCVD treatment landscape over the coming years.

• Promising Atherosclerotic Cardiovascular Disease therapies in clinical development include Olpasiran (AMG 890), Obicetrapib (TA-8995), Apabetalone (RVX000222), Pelacarsen, Lerodalcibep, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/atherosclerotic-cardiovascular-disease-ascvd-market

Key Factors Driving the Atherosclerotic Cardiovascular Disease MarketRising Global Burden of Cardiovascular Diseases

The increasing prevalence of cardiovascular diseases worldwide is a major driver of the Atherosclerotic Cardiovascular Disease market. Aging populations, sedentary lifestyles, unhealthy dietary habits, and the growing incidence of obesity and diabetes are contributing to a larger patient population requiring long-term cardiovascular management.

Increasing Prevalence of Dyslipidemia and Metabolic Disorders

The rising incidence of hypercholesterolemia, dyslipidemia, hypertension, type 2 diabetes, and metabolic syndrome has significantly increased the risk of developing ASCVD. The growing burden of these risk factors continues to drive demand for preventive and therapeutic interventions.

Advancements in Lipid-Lowering Therapies

Continuous innovation in lipid-lowering treatments, including PCSK9 inhibitors, siRNA therapies, ATP citrate lyase inhibitors, and other next-generation agents, has expanded therapeutic options for patients who are inadequately controlled with conventional statin therapy. These advancements are supporting sustained market growth.

Expanding Pipeline of Novel Cardiovascular Therapies

A robust clinical pipeline focused on lipid metabolism, inflammation, thrombosis, and other cardiovascular pathways is driving innovation in the ASCVD market. Ongoing research into first-in-class and best-in-class therapies is expected to improve patient outcomes and broaden treatment options.

Atherosclerotic Cardiovascular Disease Competitive Landscape

The Atherosclerotic Cardiovascular Disease treatment landscape is primarily driven by lipid-lowering therapies aimed at reducing LDL-C levels, supported by antiplatelet, anticoagulant, and anti-inflammatory agents for both primary and secondary prevention. Statins remain the cornerstone of therapy, while additional treatments such as ticagrelor, rivaroxaban, and LODOCO (low-dose colchicine) play key roles in reducing thrombotic and inflammatory cardiovascular risks.

Among advanced lipid-lowering options, PCSK9-targeted therapies including Evolocumab, Alirocumab, and Inclisiran have significantly improved LDL-C control in high-risk patients requiring additional lipid reduction beyond statins. Evolocumab currently leads the PCSK9 market, while Inclisiran is gaining traction due to its twice-yearly dosing and potential adherence advantages.

Other lipid-modifying therapies such as Bempedoic acid and Icosapent ethyl further address residual cardiovascular risk. Despite strong clinical efficacy, uptake of advanced lipid-lowering therapies remains limited due to cost and reimbursement barriers. However, increasing payer alignment and the development of next-generation therapies, including oral PCSK9 inhibitors, RNA-based agents targeting lipoprotein(a), and gene-editing approaches, are expected to expand treatment options and reshape the ASCVD therapeutics market in the coming years.

Discover more about therapies set to grab major Atherosclerotic Cardiovascular Disease market share @ Atherosclerotic Cardiovascular Disease Treatment Landscape

Recent Developments in the Atherosclerotic Cardiovascular Disease Market

• In June 2026, Jiangsu Vcare PharmaTech reached a major regulatory milestone as China’s NMPA officially accepted the New Drug Application (NDA) for Sumecigrel capsule. Formerly known as Vicagrel, this Class 1 innovative oral antiplatelet drug is a new-generation P2Y12 receptor antagonist designed to treat and prevent atherosclerotic thrombotic events.

• In January 2025, Ionis Pharmaceuticals’ partner Novartis announced in its year-end earnings report that Phase III pelacarsen data were expected in the first half of 2026, with regulatory submissions planned for the second half of the year.

• In January 2025, LIB Therapeutics announced the publication of a Phase III study of lerodalcibep in HoFH in The Lancet Diabetes & Endocrinology.

• In September 2025, Menarini Group announced that the EMA had validated the Marketing Authorization Application (MAA) for obicetrapib and the obicetrapib/ezetimibe fixed-dose combination as an adjunct to diet for patients with primary hypercholesterolaemia or mixed dyslipidaemia who are unable to reach LDL-C goals with the maximum tolerated dose of a statin or who are statin-intolerant or for whom a statin is contraindicated.

What is Atherosclerotic Cardiovascular Disease?

Atherosclerotic Cardiovascular Disease (ASCVD) is a medical condition characterized by the buildup of fatty deposits (plaques) on the inner walls of arteries. These plaques consist of cholesterol, fatty substances, calcium, and other cellular waste products. Over time, the plaques can harden and narrow the arteries, which reduces blood flow to vital organs and tissues.

ASCVD is a progressive and chronic condition that can affect various arteries throughout the body, including those supplying the heart (coronary arteries), brain (cerebral arteries), and legs (peripheral arteries). The most common manifestations of ASCVD include Coronary Artery Disease (CAD), cerebrovascular disease (stroke), and Peripheral Arterial Disease (PAD).

Diagnosis is based on a combination of clinical evaluation, laboratory tests, genetic analysis, and imaging techniques. Initial assessment typically includes lipid profile testing measuring total cholesterol, LDL-C, HDL-C, and triglycerides along with additional biomarkers such as apolipoproteins, hsCRP, and lipoprotein (a) in selected patients to refine cardiovascular risk.

Management and prevention primarily focus on lifestyle modification, pharmacotherapy, and interventional procedures. Pharmacologic treatment commonly includes statins as first-line therapy, with additional agents such as ezetimibe, PCSK9 inhibitors, and omega-3 fatty acids when lipid control is inadequate. In patients with established disease or severe coronary artery blockage, revascularization procedures such as percutaneous coronary intervention or coronary artery bypass grafting may be used to restore blood flow and reduce cardiovascular complications.

Atherosclerotic Cardiovascular Disease Epidemiology Segmentation

The Atherosclerotic Cardiovascular Disease epidemiology section provides insights into the historical and current ASCVD patient pool and forecasted trends across the seven major markets. The Atherosclerotic Cardiovascular Disease market report provides epidemiological analysis for the study period 2022–2036, segmented into:

• Total Atherosclerotic Cardiovascular Disease Diagnosed Prevalent Cases

• Gender-specific Diagnosed Prevalent Cases

• Age-specific Diagnosed Prevalent Cases

• Comorbidity-specific Diagnosed Prevalent Cases

• Systemic Inflammation Cases

Scope of the Atherosclerotic Cardiovascular Disease Market Report

• Therapeutic Assessment: Current marketed and emerging therapies for Atherosclerotic Cardiovascular Disease

• Atherosclerotic Cardiovascular Disease Market Dynamics: Key market forecast assumptions, pricing trends, analogue assessment, therapy uptake, and market outlook

• Key Companies: Amgen/Arrowhead Pharmaceuticals, NewAmsterdam Pharma and Menarini Group, Resverlogix, Ionis Pharmaceuticals/Novartis, LIB Therapeutics, Sanofi/Regeneron Pharmaceuticals, AstraZeneca, Merck, Novo Nordisk, and others

• Key Therapies: Evolocumab (REPATHA), Inclisiran (LEQVIO), Alirocumab (PRALUENT), Bempedoic acid (NEXLETOL/NILEMDO), Rivaroxaban (XARELTO), Olpasiran (AMG 890), Obicetrapib (TA-8995), Apabetalone (RVX000222), and others

• Competitive Intelligence Analysis: SWOT analysis and Conjoint analysis

• Unmet Needs, KOL’s Views, Analyst’s Views, Atherosclerotic Cardiovascular Disease Market Access and Reimbursement

To know more about Atherosclerotic Cardiovascular Disease companies working in the treatment market, visit @ Atherosclerotic Cardiovascular Disease Clinical Trials and Therapeutic Assessment

Table of Contents

• Atherosclerotic Cardiovascular Disease Market Report Introduction

• Executive Summary for Atherosclerotic Cardiovascular Disease

• SWOT Analysis of Atherosclerotic Cardiovascular Disease

• Atherosclerotic Cardiovascular Disease Patient Share (%) Overview at a Glance

• Atherosclerotic Cardiovascular Disease Market Overview at a Glance

• Atherosclerotic Cardiovascular Disease Background and Overview

• Atherosclerotic Cardiovascular Disease Epidemiology and Patient Population

• Country-Specific Patient Population of Atherosclerotic Cardiovascular Disease

• Atherosclerotic Cardiovascular Disease Current Treatment and Medical Practices

• Atherosclerotic Cardiovascular Disease Unmet Needs

• Atherosclerotic Cardiovascular Disease Emerging Therapies

• Atherosclerotic Cardiovascular Disease Market Outlook

• Country-Wise Atherosclerotic Cardiovascular Disease Market Analysis (2022–2036)

• Atherosclerotic Cardiovascular Disease Market Access and Reimbursement of Therapies

• Atherosclerotic Cardiovascular Disease Market Drivers

• Atherosclerotic Cardiovascular Disease Market Barriers

• Atherosclerotic Cardiovascular Disease Appendix

• Atherosclerotic Cardiovascular Disease Report Methodology

• DelveInsight Capabilities

• Disclaimer

• About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/